Incannex Healthcare Ltd ADR Cash Flow Conversion Efficiency
Incannex Healthcare Ltd ADR cash flow conversion efficiency. Based on the latest financial reports, Incannex Healthcare Ltd ADR (IXHL) has a cash flow conversion efficiency ratio of -0.033x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.46 Million) by net assets ($75.23 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Incannex Healthcare Ltd ADR (2006–2025)
Cash flow conversion efficiency of Incannex Healthcare Ltd ADR from 2006 to 2025. This chart illustrates how Incannex Healthcare Ltd ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. View IXHL stock price and chart for real-time trading data and today's change.
Incannex Healthcare Ltd ADR Cash Flow Conversion Ratio Explained
Incannex Healthcare Ltd ADR cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Incannex Healthcare Ltd ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Incannex Healthcare Ltd ADR ranked by their cash flow conversion efficiency. Also see IXHL company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ausquest Ltd
AU:AQD
|
-0.031x |
|
KB No.2 Special Purpose Acq
KQ:192250
|
-0.002x |
|
FOODWELL Co. Ltd
KQ:005670
|
0.092x |
|
AlphaTime Acquisition Corp Ordinary Shares
NASDAQ:ATMC
|
-0.001x |
|
Wing Yip Food (China) Holdings Group Limited
KQ:900340
|
-0.005x |
|
Domiki Kritis S.A.
AT:DOMIK
|
0.028x |
|
Openbase Inc
KQ:049480
|
-0.023x |
|
Korea Electronic Certification Authority Inc
KQ:041460
|
0.036x |
Annual Cash Flow Conversion Efficiency for Incannex Healthcare Ltd ADR (2006–2025)
The table below shows the annual cash flow conversion efficiency of Incannex Healthcare Ltd ADR from 2006 to 2025. Review Incannex Healthcare Ltd ADR free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $13.39 Million | $-12.51 Million | -0.935x | +33.84% |
| 2024-06-30 | $11.22 Million | $-15.85 Million | -1.413x | -173.67% |
| 2023-06-30 | $31.34 Million | $-16.18 Million | -0.516x | -44.56% |
| 2022-06-30 | $36.00 Million | $-12.85 Million | -0.357x | +66.51% |
| 2021-06-30 | $6.44 Million | $-6.87 Million | -1.066x | +40.42% |
| 2020-06-30 | $2.17 Million | $-3.89 Million | -1.789x | -133.91% |
| 2019-06-30 | $-418.90K | $-2.21 Million | 5.277x | -32.23% |
| 2018-06-30 | $-385.29K | $-3.00 Million | 7.786x | -51.05% |
| 2017-06-30 | $-169.45K | $-2.70 Million | 15.904x | +1629.81% |
| 2016-06-30 | $-700.36K | $-643.93K | 0.919x | +134.14% |
| 2015-06-30 | $478.47K | $-1.29 Million | -2.693x | -1299.64% |
| 2014-06-30 | $1.74 Million | $390.60K | 0.224x | +163.32% |
| 2013-06-30 | $13.55 Million | $-4.80 Million | -0.355x | -6.14% |
| 2012-06-30 | $20.10 Million | $-6.71 Million | -0.334x | -71.39% |
| 2011-06-30 | $15.23 Million | $-2.97 Million | -0.195x | -37.01% |
| 2010-06-30 | $12.29 Million | $-1.75 Million | -0.142x | +48.14% |
| 2009-06-30 | $6.58 Million | $-1.80 Million | -0.274x | -20.98% |
| 2008-06-30 | $9.51 Million | $-2.16 Million | -0.227x | -305.31% |
| 2007-06-30 | $6.64 Million | $-371.63K | -0.056x | +6.01% |
| 2006-06-30 | $1.34 Million | $-79.83K | -0.060x | -- |
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more